CV Therapeutics Launches Ranexa
March 24 2006 - 7:00AM
PR Newswire (US)
First New Pharmaceutical Approach for Chronic Angina in More Than
20 Years Now Available in Pharmacies PALO ALTO, Calif., March 24
/PRNewswire-FirstCall/ -- CV Therapeutics, Inc. (NASDAQ:CVTX)
announced today that its sales force is now promoting Ranexa(TM)
(ranolazine extended-release tablets) to cardiology specialists in
the United States. The product is now available in pharmacies.
Ranexa is approved as second-line treatment for chronic angina and
has antianginal and anti-ischemic effects that do not depend upon
reductions in heart rate or blood pressure. "This is a long-awaited
day for angina patients, their families and the cardiology
community who have hoped for a new pharmaceutical approach to treat
chronic angina," said Louis G. Lange, M.D., Ph.D., CV Therapeutics
chairman and chief executive officer. "I would also like to thank
our employees and collaborators who have been dedicated to bringing
this important new therapy to patients." Chronic angina is a
serious and debilitating heart condition, usually associated with
coronary artery disease and marked by repeated and sometimes
unpredictable attacks of chest pain. Approximately 6.5 million
people in the United States have chronic angina, and 400,000 new
cases are diagnosed annually, according to the American Heart
Association. Ranexa is approved for the treatment of chronic
angina. According to the approved labeling, because Ranexa prolongs
the QT interval, it should be reserved for patients who have not
achieved an adequate response with other antianginal drugs. Ranexa
should be used in combination with amlodipine, beta-blockers or
nitrates. The effect on angina rate or exercise tolerance appeared
to be smaller in women than men. Complete prescribing information
for Ranexa, including detailed safety and dosage information are
available at http://www.ranexa.com/. About CV Therapeutics CV
Therapeutics, Inc., headquartered in Palo Alto, California, is a
biopharmaceutical company focused on applying molecular cardiology
to the discovery, development and commercialization of novel, small
molecule drugs for the treatment of cardiovascular diseases. CV
Therapeutics' approved products include Ranexa(TM) (ranolazine
extended-release tablets) and ACEON(R) (perindopril erbumine)
Tablets. Ranexa is approved for the treatment of chronic angina in
patients who have not achieved an adequate response with other
antianginal drugs, and should be used in combination with
amlodipine, beta-blockers or nitrates. In addition, CV Therapeutics
co-promotes ACEON(R), an ACE inhibitor, for reduction of the risk
of cardiovascular mortality or nonfatal myocardial infarction in
patients with stable coronary artery disease and treatment of
essential hypertension. CV Therapeutics also has other clinical and
preclinical drug development candidates and programs, including
regadenoson, which is being developed for potential use as a
pharmacologic stress agent in myocardial perfusion imaging studies.
Regadenoson has not been approved for marketing by any regulatory
authorities. Except for the historical information contained
herein, the matters set forth in this press release, including
statements as to commercialization of products, are forward-looking
statements within the meaning of the "safe harbor" provisions of
the Private Securities Litigation Reform Act of 1995. These
forward-looking statements are subject to risks and uncertainties
that may cause actual results to differ materially, including,
early stage of development; regulatory review and approval of our
products; special protocol assessment agreements; the conduct and
timing of clinical trials; commercialization of products; market
acceptance of products; product labeling; concentrated customer
base; and other risks detailed from time to time in CV
Therapeutics' SEC reports, including its Annual Report on Form 10-K
for the year ended December 31, 2005. CV Therapeutics disclaims any
intent or obligation to update these forward-looking statements.
DATASOURCE: CV Therapeutics, Inc. CONTACT: investors, Christopher
Chai, Vice President, Treasury and Investor Relations, or
+1-650-384-8560, or media, John Bluth, Senior Director, Corporate
Communications, +1-650-384-8850, both of CV Therapeutics, Inc. Web
site: http://www.cvt.com/
Copyright
CV Therapeutics (NASDAQ:CVTX)
Historical Stock Chart
From Jun 2024 to Jul 2024
CV Therapeutics (NASDAQ:CVTX)
Historical Stock Chart
From Jul 2023 to Jul 2024